Tonix Pharmaceuticals Presents Phase 1 Data and Plans for Adaptive Phase 2 Study of TNX-4800 for Lyme Disease Prevention

Tonix Pharmaceuticals Unveils Phase 1 Data, Outlines Adaptive Phase 2 for TNX-4800

Tonix Pharmaceuticals announced the presentation of Phase 1 data for TNX-4800, a long-acting human monoclonal antibody for Lyme disease prevention, and detailed plans for an adaptive Phase 2 field study. The Phase 1 study (NCT04863287) in 44 healthy adults demonstrated TNX-4800 was generally safe and well-tolerated, with rapid systemic absorption and quantifiable concentrations up to 12 months. Based on these pharmacokinetic results, Tonix plans to initiate a randomized, double-blind, placebo-controlled Phase 2 study in the first half of 2027, pending FDA agreement. This study will evaluate a two-dose subcutaneous regimen of TNX-4800, aiming to prevent Lyme disease for six months as its primary endpoint, targeting adolescents and adults in U.S. Lyme-endemic areas.

• Phase 1 Safety and Pharmacokinetics: The Phase 1 study (NCT04863287) in 44 healthy adults showed TNX-4800 was generally safe and well-tolerated across single subcutaneous doses from 0.5 to 10 mg/kg. Key pharmacokinetic findings included a ~25-fold increase in drug exposure for a 20-fold dose increase, rapid systemic absorption within two days, and sustained quantifiable serum concentrations for up to 12 months in most participants. Transient anti-drug antibodies were observed in less than 10% of participants without impacting PK.
• Adaptive Phase 2 Study Design: Tonix plans to initiate a randomized, double-blind, placebo-controlled adaptive Phase 2 field study in the first half of 2027, pending FDA agreement. The study will test a two-dose subcutaneous regimen of TNX-4800, with an initial Spring dose followed by a Summer booster two months later. The primary endpoint is the prevention of confirmed Lyme disease for six months following the initial dose, targeting adolescents and adults aged 16 and older in U.S. Lyme-endemic regions.
• Mechanism of Action and Differentiating Factors: TNX-4800 is a long-acting bactericidal human monoclonal antibody engineered with an extended half-life, targeting the outer surface protein A (OspA) of Borrelia burgdorferi. It is designed to provide passive immunity against Lyme disease within two days, offering a potential advantage over traditional vaccines that require longer immunization schedules and rely on the recipient's immune system to generate antibodies. The company believes this rapid, passive immunity could improve adherence and uptake compared to previous vaccine approaches.

The Growing Burden of Lyme Disease and Unmet Prevention Needs

Current Lyme disease prevention faces significant obstacles despite the growing disease burden and associated healthcare costs. Multiple systematic reviews highlight substantial gaps in available prevention strategies, from the absence of human vaccines to limitations in existing interventions.

• Lack of human vaccination options - No vaccine is currently available for humans, despite vaccination being recognized as the most effective prevention intervention; previous OspA-based vaccines in the 1990s were safe and effective in phase III trials but failed due to poor public acceptance

• Insufficient evidence base for prevention interventions - Systematic reviews indicate low-quality evidence overall for prevention strategies, with too few studies available to reach robust conclusions about intervention effectiveness

• Limited efficacy of educational approaches - While educational interventions successfully improve adults' knowledge and preventative behaviors, findings are mixed for children, and importantly, knowledge changes typically do not translate into lower Lyme disease incidence rates

• Uncertainty around antibiotic prophylaxis protocols - Previous meta-analyses lack sufficient statistical power to demonstrate antibiotic prophylaxis efficacy, and extrapolation of North American approaches to Europe is complicated by differences in Borrelia genospecies and tick species

• Healthcare provider knowledge gaps - Primary care providers show limited ability to identify tick species, with only 10.5% correctly identifying engorged adult female blacklegged ticks and less than half identifying the three pathogens most frequently transmitted by these ticks

• Inconclusive environmental control methods - No evidence supports deer culling effectiveness, and evidence remains inconclusive for acaricide applications to deer, limiting options for ecological intervention approaches

TNX-4800: Promising Phase 1 Data Informs Adaptive Phase 2 Design

Recent clinical investigations in Lyme disease prevention have focused primarily on vaccine development, with the VLA15 vaccine representing the most advanced preventive intervention currently under study. A comprehensive meta-analysis of three randomized controlled trials involving 5,907 participants (4,500 receiving VLA15, 1,407 receiving placebo) evaluated this novel recombinant vaccine targeting six OspA serotypes. The systematic review, registered in PROSPERO and conducted following PRISMA guidelines with literature searches through May 2025, represents the most robust evidence base for Lyme disease prevention to date.

The VLA15 vaccine demonstrated strong immunogenicity with consistently elevated IgG levels, geometric mean titers, and seroconversion rates compared to placebo. However, safety analysis revealed significantly higher risks of adverse events among VLA15 recipients, including fever (RR 2.65, 95% CI: 1.77-3.96), headache (RR 1.40, 95% CI: 1.21-1.62), fatigue (RR 1.33, 95% CI: 1.15-1.55), and arthralgia (RR 2.50, 95% CI: 1.67-3.76), all with p-values < 0.0001. Subgroup analysis identified a dose-response relationship for arthralgia, particularly at 135 μg and 180 μg doses, though these adverse events were characterized as mild-to-moderate and the vaccine maintained an acceptable safety profile.

Complementary research has examined post-exposure prophylaxis practices through a retrospective chart review conducted in rural Wisconsin from 2022-2024, analyzing 2,404 prophylaxis prescriptions for single-dose doxycycline (200 mg within 72 hours of tick removal). This study revealed significant implementation challenges, with manual abstraction of 155 prescribing events showing doxycycline was indicated in only 12% of cases, while the remainder were classified as possibly indicated or not indicated due to suboptimal documentation and nonadherence to IDSA guidelines. The analysis highlighted persistent gaps in real-world prevention practices despite established clinical recommendations for post-exposure prophylaxis in endemic areas.

TNX-4800: A Novel Passive Immunity Approach for Lyme Prevention

The Lyme disease prevention landscape has undergone significant evolution over the past five years, particularly in vaccine development efforts. VLA15-221 vaccine advanced to phase II clinical trials by 2024, with immunogenicity and safety data announced that year, while another unnamed vaccine was reported to be in phase III clinical trials as of 2022. However, despite these developmental advances, no vaccine against Lyme disease remains currently available for clinical use as of 2023-2024, leaving post-exposure prophylaxis as the primary prevention strategy.

Post-exposure prophylaxis guidelines have become more refined, with the 2020 IDSA guidelines recommending a single 200 mg dose of doxycycline within 72 hours of tick removal following high-risk bites. Real-world implementation studies from 2022-2024 in rural Wisconsin revealed challenges in clinical practice, with doxycycline indicated in only 12% of cases upon manual review due to incomplete documentation and guideline nonadherence. Despite these implementation challenges, mechanical tick removal within 36 hours of attachment remains strongly recommended, and antibiotic prophylaxis administered within 72 hours of blacklegged tick bite has demonstrated preventive efficacy.

The pediatric prevention landscape has experienced notable shifts, with expanded acceptance of doxycycline use in younger populations. The 2018 American Academy of Pediatrics guidelines established that doxycycline courses of up to 3 weeks are safe in children of all ages, and by 2025, age restrictions for doxycycline treatment of neuroborreliosis in children under 8 years were removed. This guideline evolution is reflected in prescribing patterns, with doxycycline use in children under 8 years increasing dramatically from 6.9% in 2015 to 67.9% in 2023, demonstrating a substantial shift in clinical practice toward broader doxycycline utilization for Lyme disease prevention across all pediatric age groups.

Tonix Charts New Course in Lyme Prevention with Long-Acting Antibody

The recent announcement from Tonix Pharmaceuticals regarding its Phase 1 data for TNX-4800 marks an important moment in the pursuit of effective Lyme disease prevention. With Lyme disease continuing to pose a significant public health challenge, particularly in endemic regions, the prospect of a long-acting human monoclonal antibody offers a novel and potentially transformative prophylactic strategy. The Phase 1 study demonstrated that TNX-4800 was generally safe and well-tolerated, with a pharmacokinetic profile showing quantifiable concentrations for up to 12 months. This sustained presence in the body is crucial for a preventative agent, suggesting the potential for a convenient, two-dose regimen to provide six months of protection, as targeted in the upcoming Phase 2 study.

For Tonix, this venture into infectious diseases represents a strategic expansion of its pipeline. The company, already with an approved product for fibromyalgia and other assets in development for central nervous system disorders, is clearly diversifying its therapeutic focus. This move not only broadens its market reach but also leverages potential expertise in developing long-acting formulations, a capability that could be applied to other indications in the future.

However, the path forward is not without its considerations. While the Phase 1 results are encouraging, the transition to a larger, adaptive Phase 2 field study introduces inherent clinical development risks. Efficacy in preventing Lyme disease, as well as the comprehensive safety profile in a broader population, still needs to be established. Furthermore, the initiation of this pivotal Phase 2 study is contingent on FDA agreement, a regulatory step that could influence timelines and study design. As the pharmaceutical landscape evolves, the successful navigation of these clinical and regulatory hurdles will be paramount for TNX-4800 to realize its potential as a significant advancement in preventing Lyme disease.